Showing results (201-210 of 409) with videos related to
Sort By:
Pageof 41
Neurology|November 14, 2019
Variation in cognitive function over time in Gaucher disease type 3Alta M Steward, Edythe Wiggs, Taylor Lindstrom, et al.Muscle & Nerve|April 4, 2006
Enzyme replacement therapy and intraepidermal innervation density in Fabry diseaseRaphael Schiffmann, Peter Hauer, Barbara Freeman, et al.Clinical Nutrition (Edinburgh, Scotland)|July 11, 2023
Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial diet adherence & outcomesEmma Wetmore, Diana Lehner-Gulotta, Brian Florenzo, et al.European Journal of Neurology|March 20, 2024
Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: A systematic review and meta-analysisCaroline Hagbohm, Russell Ouellette, Eoin P Flanagan, et al.Biochemical and Biophysical Research Communications|May 29, 2007
Screening for pharmacological chaperones in Fabry diseaseSang-Hoon Shin, Gary J Murray, Stefanie Kluepfel-Stahl, et al.Neurology(R) Neuroimmunology & Neuroinflammation|July 6, 2022
Younger Age at Onset Is Associated With Worse Long-term Behavioral Outcomes in Anti-NMDA Receptor EncephalitisAnusha Yeshokumar, Eliza Gordon-Lipkin, Ana Arenivas, et al.Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2022
Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefitsJ Nicholas Brenton, Diana Lehner-Gulotta, Emma Woolbright, et al.Proceedings of the National Academy of Sciences of the United States of America|February 16, 2007
Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalitiesDavid F Moore, Oleg V Krokhin, Ronald C Beavis, et al.Journal of Inherited Metabolic Disease|March 11, 2016
Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry miceXing-Li Meng, Taniqua S Day, Nathan McNeill, et al.Advances in Therapy|May 27, 2024
Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP)Raphael Schiffmann, Eugen Mengel, Mary Wallace, et al.Pageof 41